2001-01-02
Microscopic
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Fine Chemical ManufacturingPharmaceuticals and Chemical IntermediatesFertilizers and Agrochemicals
Country / Region:
China
Company Type:
State-owned holding enterpriseSpecialized refined distinctive and innovative enterprises
Registered Capital:
$2.16 million
Company Capability: Chemical Technology & Patents、Process Technology Development、Technology Transfer
Xilie Chemical (Dalian) Co., Ltd. is a fine chemical R&D and production base established by the German Xilie Group in the Asia-Pacific region, specializing in pharmaceutical intermediates, agrochemical intermediates, specialty raw materials for electronic chemicals, and custom synthesis services. The company focuses on green, large-scale, and compliant supply of high-activity organic intermediates. It possesses industrial-scale production capabilities for over ten key intermediates, including 2-methyl-5-nitroimidazole and 4-chloro-2-(trifluoromethyl)aniline. Its flagship products have been registered with the U.S. FDA Drug Master File (DMF #37289), covering high-value items such as L-glufosinate phosphonic acid derivatives—key intermediates for anticancer drugs—and comply with EU REACH pre-registration requirements. Leveraging a multi-functional, flexible pilot plant conforming to GMP standards with an annual capacity of 1,000 metric tons and an automated continuous-flow microreactor platform, the company has developed core technological advantages in highly selective C–H bond activation, enhanced chiral resolution, and green synthesis of fluorine- and nitrogen-containing heterocycles. Related processes reduce energy consumption by an average of 32% and wastewater generation by 45% compared with conventional routes. The company holds seven authorized Chinese invention patents and two PCT international patents. It has obtained certification for the three major management systems—ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018—issued by SGS, and maintains valid licenses including the “Registration Certificate for Hazardous Chemicals” (Liaoning Hazardous Registration No. [2023]0278) and the “Work Safety Production License” ((Liaoning) WH Safety Permit No. [2021]02-0086). Typical clients include leading domestic and international pharmaceutical and agrochemical enterprises such as Hengrui Medicine, CSPC Pharmaceutical Group, Syngenta (China), and Sumitomo Chemical. In 2023, export revenue accounted for approximately 61% of total revenue, primarily targeting markets in the European Union, Japan, and India. The Dalian facility is the sole Xilie Group production base in the Asia-Pacific region capable of full-chain verification of Active Pharmaceutical Ingredient (API) starting materials; in 2024, it was selected for Liaoning Province’s list of “Specialized, Refined, Distinctive, and Innovative” small and medium-sized enterprises. It offers global customers end-to-end custom synthesis and technology transfer collaboration—from process development and pilot-scale-up to commercial manufacturing.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































